Assessment of lipid peroxidation and total antioxidant capacity in patients with breast cancer

Abdullatif Taha Babakr , Mohamed Mahmoud Nour Eldein

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002284

PDF (4304KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002284 DOI: 10.37349/etat.2025.1002284
Original Article
research-article
Assessment of lipid peroxidation and total antioxidant capacity in patients with breast cancer
Author information +
History +
PDF (4304KB)

Abstract

Aim: Breast cancer (BC), a disease in which abnormal breast cells grow out of control and form tumors, is a prevalent life-threatening disease worldwide. Oxidative stress has been implicated in the development and progression of various cancers, including BC. Assessing lipid peroxidation and overall antioxidant status in BC offers valuable information on disease progression, patient prognosis, and the effectiveness of therapeutic options.

Methods: A total of 150 women were categorized into three groups: normal, benign mass, and BC. Participants were selected and evaluated at the cancer clinic; fasting blood samples were collected, and total antioxidant capacity (TAC), oxidized low-density lipoprotein (Ox-LDL), cancer antigen (CA) 15-3, and carcinoembryonic antigen (CEA) were measured. Subsequently, statistical analysis was performed to compare the levels of these parameters in different groups and examine the analytical performance of TAC and Ox-LDL in BC.

Results: In patients with malignancy, the serum level of TAC was significantly decreased compared with the benign group (8.3 U/mL and 16.04 U/mL, respectively) (P < 0.001). Healthy controls exhibited higher levels of TAC (43.4 U/mL). The levels of Ox-LDL in BC were significantly increased in both malignant and benign groups (3,831 pg/mL and 1,234 pg/mL, respectively) compared with normal controls (682 pg/mL) (P < 0.001). CEA and CA15-3 were drastically increased in the BC groups compared with the control group. A significant area under the curve was observed in the receiver operating characteristic (ROC) curve analysis for TAC (0.975, P < 0.001) and Ox-LDL (0.986, P < 0.001).

Conclusions: This study revealed that patients with BC had lower TAC and higher Ox-LDL serum levels, indicating elevated oxidative stress. These levels may serve as promising monitoring parameters in BC.

Keywords

Oxidative stress / breast cancer / antioxidants / oxidized LDL / free radicals / cancer biomarkers

Cite this article

Download citation ▾
Abdullatif Taha Babakr, Mohamed Mahmoud Nour Eldein. Assessment of lipid peroxidation and total antioxidant capacity in patients with breast cancer. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002284 DOI:10.37349/etat.2025.1002284

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022; 95: 20211033.

[2]

Nour Eldin EE, Almarzouki A, Assiri AM, Elsheikh OM, Mohamed BE, Babakr AT. Oxidized low density lipoprotein and total antioxidant capacity in type-2 diabetic and impaired glucose tolerance Saudi men. Diabetol Metab Syndr. 2014; 6: 94.

[3]

Demirci-Çekiç S, Özkan G, Avan AN, Uzunboy S, Çapanoğlu E, Apak R. Biomarkers of Oxidative Stress and Antioxidant Defense. J Pharm Biomed Anal. 2022; 209: 114477.

[4]

Babakr AT, Althubiti M. Impact of Antioxidant-Rich Diet on Decreasing Oxidized Low-Density Lipoproteins, 8-Hydroxy-2’-Deoxyguanosine and Hba1c in Saudi Men. Biomed Pharmacol J. 2023; 16.

[5]

Kangari P, Zarnoosheh Farahany T, Golchin A, Ebadollahzadeh S, Salmaninejad A, Mahboob SA, et al. Enzymatic Antioxidant and Lipid Peroxidation Evaluation in the Newly Diagnosed Breast Cancer Patients in Iran. Asian Pac J Cancer Prev. 2018; 19: 3511-5.

[6]

Didžiapetrienė J, Kazbarienė B, Tikuišis R, Dulskas A, Dabkevičienė D, Lukosevičienė V, et al. Oxidant/Antioxidant Status of Breast Cancer Patients in Pre- and Post-Operative Periods. Medicina (Kaunas). 2020; 56: 70.

[7]

Delimaris I, Faviou E, Antonakos G, Stathopoulou E, Zachari A, Dionyssiou-Asteriou A. Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin Biochem. 2007; 40: 1129-34.

[8]

Khalaf MY, Mohammed AA, Mosa AA, Arif SH, Mustafa JA. The correlation of antioxidant levels of breast cancer: A case controlled study. Medicine (Baltimore). 2021; 100: e26878.

[9]

Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov. 2021; 20: 689-709.

[10]

Fatani SH, Babakr AT, NourEldin EM, Almarzouki AA. Lipid peroxidation is associated with poor control of type-2 diabetes mellitus. Diabetes Metab Syndr. 2016; 10: S64-7.

[11]

Babakr AT. Scavenger Receptors: Different Classes and their Role in the Uptake of Oxidized Low-Density Lipoproteins. Biomed Pharmacol J. 2024; 17: 699-712.

[12]

Cserni G, Chmielik E, Cserni B, Tot T. The new TNM-based staging of breast cancer. Virchows Arch. 2018; 472: 697-703.

[13]

Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat. 2000; 59: 163-70.

[14]

Jelic MD, Mandic AD, Maricic SM, Srdjenovic BU. Oxidative stress and its role in cancer. J Cancer Res Ther. 2021; 17: 22-8.

[15]

Delrieu L, Touillaud M, Pérol O, Morelle M, Martin A, Friedenreich CM, et al. Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer. Oxid Med Cell Longev. 2021; 2021: 6694594.

[16]

de Oliveira ST, Bessani MP, Scandolara TB, Silva JC, Kawassaki ACB, Fagotti PAF, et al. Systemic lipid peroxidation profile from patients with breast cancer changes according to the lymph nodal metastasis status. Oncoscience. 2022; 9: 1-10.

[17]

Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012; 2012: 137289.

[18]

Liu X, Zhao J, Zheng R. DNA damage of tumor-associated lymphocytes and total antioxidant capacity in cancerous patients. Mutat Res. 2003; 539: 1-8.

[19]

Zhang F, Deng Y, Drabier R. Multiple biomarker panels for early detection of breast cancer in peripheral blood. Biomed Res Int. 2013; 2013: 781618.

[20]

Hasan D. Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients. J Circ Biomark. 2022; 11: 57-63.

[21]

Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006; 52: 345-51.

[22]

Postovit L, Widmann C, Huang P, Gibson SB. Harnessing Oxidative Stress as an Innovative Target for Cancer Therapy. Oxid Med Cell Longev. 2018; 2018: 6135739.

[23]

Mobley JA, Brueggemeier RW. Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis. 2004; 25: 3-9.

[24]

Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents--DNA adducts and mutations. J Natl Cancer Inst Monogr. 2000: 75-93.

[25]

Tahmasebpour N, Hosseinpour Feizi MA, Ziamajidi N, Pouladi N, Montazeri V, Farhadian M, et al. Association of Omentin-1 with Oxidative Stress and Clinical Significances in Patients with Breast Cancer. Adv Pharm Bull. 2020; 10: 106-13.

[26]

Sova H, Jukkola-Vuorinen A, Puistola U, Kauppila S, Karihtala P. 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer. Br J Cancer. 2010; 102: 1018-23.

[27]

Althubiti M, Elzubier M, Alotaibi GS, Althubaiti MA, Alsadi HH, Alhazmi ZA, et al. Beta 2 microglobulin correlates with oxidative stress in elderly. Exp Gerontol. 2021; 150: 111359.

[28]

Senoner T, Dichtl W. Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? Nutrients. 2019; 11: 2090.

PDF (4304KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉